Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Other Operating Expenses data on file, last reported at $4.0 million in Q1 2026.

• Quarterly Other Operating Expenses rose 302.71% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 233.63% YoY) and the FY2025 annual result came in at $9.0 million, up 292.74% from the prior year.
• Other Operating Expenses grew to $4.0 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $108.0 million in Q1 2022 to a low of -$121.5 million in Q4 2022.
• A 5-year average of -$2.5 million and a median of -$312000.0 in 2022 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 22006.69% in 2022, down 1063.54% in 2022.
• Tracing BMRN's Other Operating Expenses over 5 years: stood at -$121.5 million in 2022, then jumped by 83.62% to -$19.9 million in 2023, then advanced by 26.28% to -$14.7 million in 2024, then surged by 106.99% to $1.0 million in 2025, then surged by 286.44% to $4.0 million in 2026.
• The last three Other Operating Expenses figures came in at $4.0 million (Q1 2026), $1.0 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.